Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (9.998.170 €): Wirt gerichtete Medizin bei invasiver Pilzinfektion Hor01.01.2020 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Wirt gerichtete Medizin bei invasiver Pilzinfektion
Despite novel treatment options and development of diagnostic tools invasive fungal infections (IFI) are still associated with an unacceptably high mortality and morbidity. Experts believe that a host directed approach is needed to overcome this problem. HDM-FUN proposes a transdisciplinary approach to identify host-pathogen factors (HPFs) needed for host directed medical interventions in IFI and will be the first of its kind. The overall concept is to identify host-pathogen factors in the setting of immunotherapy and prophylaxis that will allow the design for tailored novel therapeutic and preventive host-directed medicine approaches for patients with lethal invasive fungal infection in the intensive care. Specific objectives: 1. To identify host-pathogen factors that correlate with disease, and correlate them with preventive or immunotherapy- based strategies to stratify patients for personalized host-directed treatment options. 2. Two clinical trials of host-directed medicine approaches; an immunotherapy trial in patients with candidemia and a prospective observational trial for prophylaxis in patients with influenza at risk for aspergillosis. 3. To set-up a centrally managed biobank with samples of the patients enrolled in both clinical trials, and to standardize experimental procedures, protocols and centralize analysis. 4. To establish a unique infrastructure aimed to: explore host-directed medicine approaches in IFI, evaluate their impact on patients and health care, translate research efforts to clinical practice by designing point of care tests and teaching medical professionals. HDM-FUN brings together top scientists and clinical researchers to unravel host factors (genetics and transcription), immune modulators (metabolome, microbiome), and host pathogen interactions (genetics, metabolomics, immunology, signalling pathways, phagosome biogenesis, and inflammasome regulation) that determine the susceptibility and outcome of patients with fungal infection.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Centre Hospitalier Universitaire Vaudois | 456.500 € |
| Duke University | 592.750 € |
| Hycult Biotechnology B.V. | 400.000 € |
| Idryma Technologias Kai Erevnas | 319.750 € |
| Imagine Institut des Maladies Genetiques Necker Enfants Malades Fondation | 633.124 € |
| Innovation Acta Srl | 350.500 € |
| Institut Pasteur | 692.185 € |
| Johann Wolfgang Goethe-Universitaet Frankfurt AM Main | 198.150 € |
| Julius-Maximilians-Universitat Wurzburg | 319.950 € |
| Katholieke Universiteit Leuven | 1.271.626 € |
| Leibniz-Institut FUR Naturstoff-Forschung UND Infektionsbiologie e. V. Hans-Knoll-Institut | 319.700 € |
| Stichting Radboud Universitair Medisch Centrum | 3.288.700 € |
| Stichting Radboud Universiteit | 0,00 € |
| The University Court of the University of Aberdeen | 320.010 € |
| Universidade do Minho | 319.625 € |
| Universita Degli Studi Di Perugia | 322.450 € |
| Universitatea de Medicina si Farmacie Iuliu Hatieganu Cluj-Napoca | 193.150 € |
| Universite Paris Cite | 0,00 € |
Quelle: https://cordis.europa.eu/project/id/847507
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.